Can psychedelics restore consciousness after brain trauma?
Researchers explore the potential of psychedelic therapies for people in minimally conscious states.
Read morePsilocybin Mushrooms and Bipolar Disorder
A new study published in the Journal of Psychopharmacology is the first to characterize the psychological impacts of psilocybin among people with bipolar disorder.
The findings indicate that many people with bipolar disorder who consume psilocybin, the primary psychoactive component of psychedelic “magic mushrooms,” believe that the experience is helpful. However, many also report adverse outcomes, such as manic symptoms.
Read moreLSD vs. Ayahuasca
LSD and ayahuasca have distinct therapeutic benefits. This article explores how these experiences differ and which may be more appropriate for you.
Read moreA Bad Trip
Jules Evans of The Challenging Psychedelic Experiences Project discusses the project and what he and his co-researchers hope to learn from the data they collect.
Read moreThe Key to Happiness
Researchers have followed over 700 people since 1938 to find the keys to happiness.
Read moreThe Importance of Indigenous Knowledge
This can’t be emphasized enough: Various indigenous cultures found, used, and promoted plant-based psychedelics for human wellness and spiritual development for thousands of years, in almost every place where humans lived on the planet.
Read morePsychedelic Insights and Delusions
"Aha” moments in psychedelic therapy can offer unique insight and perspective. But some insights are false and others may ring true.
Read morePodcast: Dr. Andrew Weil Talks Psychedelics
Check out this podcast from Psychedelics Today~~ with New York Times best-selling author, pioneer in the field of integrative medicine, and overall legend in the health and wellness space: Andrew Weil, M.D.
Read morePsychedelics and Traumatic Brain Injury
DMT and a Shared Alien Universe?
As The New Republic reports, the Colorado-based psychedelics startup Medicinal Mindfulness is currently seeking approval from the Food and Drug Administration to study what it's calling DMTx, an extended-state, intravenous drip version of DMT that will induce in users trips far longer than the roughly five-to-ten minute experiences the drug typically provides.
DMT carries with it a ton of intriguing qualities, including that studies suggest our brains produce the drug naturally and that those who have taken it often experience variations on the same theme: entering what seems to be another plane or dimension replete with its own ethereal beings, sometimes referred to as "machine elves," who are there to welcome them.
Read moreMDMA-Assisted Therapy and PTSD
Here’s the official statement from MAPS!
The results confirmed findings from MAPP1; no serious adverse events were observed among the participants
In a first for psychedelic-assisted therapy trials, more than half of MAPP2 participants identify as people of color